CNR Institutional Research Information System

FONTI, ROSA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 1.740
NA - Nord America 1.188
EU - Europa 436
SA - Sud America 255
AF - Africa 27
Continente sconosciuto - Info sul continente non disponibili 24
OC - Oceania 2
Totale 3.672
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.103
SG - Singapore 656
CN - Cina 393
HK - Hong Kong 247
BR - Brasile 195
VN - Vietnam 146
IT - Italia 138
BD - Bangladesh 100
FR - Francia 95
NL - Olanda 82
KR - Corea 67
JP - Giappone 40
CA - Canada 33
DE - Germania 29
GB - Regno Unito 26
FI - Finlandia 19
IN - India 19
EC - Ecuador 17
MX - Messico 16
CO - Colombia 15
AR - Argentina 12
ID - Indonesia 11
ZA - Sudafrica 11
CR - Costa Rica 9
IQ - Iraq 9
ES - Italia 7
IL - Israele 7
CL - Cile 6
PH - Filippine 5
TR - Turchia 5
TT - Trinidad e Tobago 5
UA - Ucraina 5
AZ - Azerbaigian 4
IE - Irlanda 4
JM - Giamaica 4
RU - Federazione Russa 4
SA - Arabia Saudita 4
AT - Austria 3
DO - Repubblica Dominicana 3
EG - Egitto 3
KH - Cambogia 3
KZ - Kazakistan 3
MA - Marocco 3
MD - Moldavia 3
MN - Mongolia 3
MY - Malesia 3
PK - Pakistan 3
PL - Polonia 3
PT - Portogallo 3
PY - Paraguay 3
SE - Svezia 3
SV - El Salvador 3
VE - Venezuela 3
AE - Emirati Arabi Uniti 2
AU - Australia 2
DZ - Algeria 2
GT - Guatemala 2
HN - Honduras 2
LA - Repubblica Popolare Democratica del Laos 2
LT - Lituania 2
PE - Perù 2
TH - Thailandia 2
TN - Tunisia 2
TW - Taiwan 2
UZ - Uzbekistan 2
XK - ???statistics.table.value.countryCode.XK??? 2
AL - Albania 1
BB - Barbados 1
BG - Bulgaria 1
BO - Bolivia 1
BS - Bahamas 1
CI - Costa d'Avorio 1
CU - Cuba 1
DK - Danimarca 1
DM - Dominica 1
EE - Estonia 1
ET - Etiopia 1
GA - Gabon 1
GP - Guadalupe 1
GR - Grecia 1
IM - Isola di Man 1
IS - Islanda 1
JO - Giordania 1
KE - Kenya 1
LC - Santa Lucia 1
LV - Lettonia 1
NI - Nicaragua 1
NP - Nepal 1
PA - Panama 1
RO - Romania 1
RS - Serbia 1
SC - Seychelles 1
SN - Senegal 1
UY - Uruguay 1
Totale 3.650
Salva come PNG Salva come JPEG
Città #
Singapore 406
Santa Clara 322
Hong Kong 244
Hefei 130
San Jose 111
Beijing 100
Ashburn 95
Lauterbourg 72
Seoul 67
Ho Chi Minh City 56
Los Angeles 45
Hanoi 38
Tokyo 29
New York 22
Naples 17
Milan 14
Buffalo 12
Chicago 12
São Paulo 12
Dallas 11
Düsseldorf 11
Helsinki 11
Atlanta 10
Rome 10
Orem 9
Minamishinagawa 8
Brooklyn 7
Frankfurt am Main 7
Mexico City 7
Rio de Janeiro 7
Belleville 6
Casandrino 6
Haiphong 6
Johannesburg 6
Queens 6
Quito 6
Suzhou 6
The Bronx 6
Bauru 5
Bengaluru 5
Council Bluffs 5
Da Nang 5
Guarulhos 5
Guayaquil 5
Hangzhou 5
San Antonio 5
Shanghai 5
Toronto 5
Abbeville 4
Baku 4
Biên Hòa 4
Bologna 4
Charlotte 4
Columbus 4
Crowley 4
Dublin 4
Guangzhou 4
Lappeenranta 4
Leesburg 4
Medellín 4
Memphis 4
Montreal 4
Philadelphia 4
Poplar 4
San José 4
Springfield 4
St Louis 4
Wingate 4
Abaetetuba 3
Baghdad 3
Belo Horizonte 3
Benito Juarez 3
Buenos Aires 3
Carapicuíba 3
Chongqing 3
Cleveland 3
Dhaka 3
Florence 3
Ha Long 3
Houston 3
Joinville 3
Jundiaí 3
Manchester 3
Miami 3
Omaha 3
Palermo 3
Paris 3
Phnom Penh 3
Phoenix 3
Porto Alegre 3
Rio Grande 3
San Francisco 3
San Salvador 3
Shenzhen 3
Stockholm 3
São Gonçalo 3
São Luís 3
Turku 3
Ulan Bator 3
Washington 3
Totale 2.176
Salva come PNG Salva come JPEG
Nome #
Total metabolic tumor volume by 18F-FDG PET/CT for the prediction of outcome in patients with non-small cell lung cancer 119
18F-FDG PET/CT, 99mTc-MIBI, and MRI in evaluation of patients with multiple myeloma 98
Monitoring Reversal of Concurrent Mechanisms of Resistance to EGFR TKIs in Non-Small Cell Lung Cancer by 18F-FLT PET/CT 97
Early reduction of 18F-FDG uptake in non-small lung cancer treated with EGFR tyrosine kinase inhibitors reflects reversal of Warburg effect and reactivation of oxidative phosphorylation. 92
Changes of Glycolytic Pathway in Response to Efficient Inhibition of EGFR Signaling in Non-small Cell Lung Cancer (NSCLC) 90
The antiproliferative effect of pasireotide LAR alone and in combination with everolimus in patients with medullary thyroid cancer: a single-center, open-label, phase II, proof-of-concept study 86
Molecular mechanisms of decreased aerobic glycolysis in non-small lung cancer treated with EGFR tyrosine kinase inhibitors. European Society for Molecular Imaging Meeting 77
Metabolic Tumor Volume assessed by 18F-FDG-PET/CT in the evaluation of plasma cell mass and prediction of outcome in patients with multiple myeloma 76
18F-FLT PET/CT for Detection of Functional Cross-talk between MET and EGFR in Non-small Cell Lung Cancer Resistant to EGFR Inhibitors 75
Inositol Trisphosphate Receptor Type 3-mediated Enhancement of EGFR and MET Cotargeting Efficacy in Non-Small Cell Lung Cancer Detected by F-18-fluorothymidine 72
Prognostic role of 18F-FDG PET/CT in the postoperative evaluation of differentiated thyroid cancer patients 72
Bone Scintigraphy and SPECT/CT in Bisphosphonate-Induced Osteonecrosis of the Jaw 70
Gefitinib, a selective, tyrosine kinase inhibitor increases 99mTc-MIBI uptake in Bcl-2 overexpressing breast cancer cells. 68
Non-invasive detection of epithelial mesenchymal transition phenotype and metastatic dissemination of lung cancer by liquid biopsy 66
18F-FDG PET/CT, 99mTc-MIBI, and MRI in the Prediction of Outcome of Patients With Multiple Myeloma: A Comparative Study 64
Non-Canonical Role of PDK1 as a Negative Regulator of Apoptosis through Macromolecular Complexes Assembly at the ER–Mitochondria Interface in Oncogene-Driven NSCLC 63
Bone Marrow uptake of 99mTc-MIBI in patients with multiple myeloma 62
Prognostic role of FDG PET/CT in patients with differentiated thyroid cancer treated with 131-iodine empiric therapy 61
A reversible shift of driver dependence from egfr to notch1 in non-small cell lung cancer as a cause of resistance to tyrosine kinase inhibitors 60
99mTc-sestamibi scintigraphy in thalidomide-treated refractory or relapsed multiple myeloma patients. 59
Preclinical imaging for targeting cancer immune evasion 59
Multimodal imaging with 18F-FDG-PET/CT and 111In-Octreotide SPECT in patients with metastatic medullary thyroid carcinoma 59
Heterogeneity of SSTR2 Expression Assessed by 68Ga-DOTATOC PET/CT Using Coefficient of Variation in Patients with Neuroendocrine Tumors 58
Imaging integrato del Mieloma Multiplo con 18FDG-PET/TC, TC99M-MIBI e RM 57
Preclinical Imaging in Targeted Cancer Therapies 53
Neutrophil Extracellular Traps as an Adhesion Substrate for Different Tumor Cells Expressing RGD-Binding Integrins 49
Coordinate modulation of glycolytic enzymes and OXPHOS by imatinib in BCR-ABL driven chronic myelogenous leukemia cells 48
Molecular imaging of drug resistance in cancer 47
Detection of Leptomeningeal Involvement by 18F-FDG-PET/CT in a Patient With Non-Hodgkin Lymphoma 46
IS 2-DEOXY-2-[18F]FLUORO-D-GLUCOSE PET/CT ACQUISITION FROM THE UPPER THIGH TO THE VERTEX OF SKULL USEFUL IN ONCOLOGICAL PATIENTS? 46
Molecular imaging for detection of sensitivity and resistance to EGFR tyrosine kinase inhibitors in non-small cell lung cancer 46
Visual and volumetric parameters by 18F-FDG-PET/CT: a head to head comparison for the prediction of outcome in patients with multiple myeloma 46
PET/CT in cancer research: from preclinical to clinical applications 45
99mTc-MIBI in the evaluation of breast cancer biology 45
Dynamic coupling of 99mtc-MIBI efflux and apoptotic pathway activation in untreated breast cancer patients 45
Early F-18-FDG uptake as a reliable imaging biomarker of T790M-mediated resistance but not MET amplification in non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors 44
PET/CT in radiation oncology 44
Combined 18F-FDG-PET/CT and 111In-Octreotide SPECT for Evaluation of Thymic Epithelial Tumors 42
Imaging of immunotherapy response in non-small cell lung cancer: challenges and perspectives 41
Tumor Detection in Syndromic NET: Zollinger-Ellison Syndrome. 41
Metastasis to the Sellar/Suprasellar Region in a Patient With Endometrial Carcinoma Detected by F-18-FDG PET/CT 40
Metabolic Tumor Volume Assessed by 18F-FDG PET/CT for the Prediction of Outcome in Patients with Multiple Myeloma 40
18F-FLT PET/CT as a surrogate biomarker for synergy quantification in EGFR targeted combination therapy of NSCLC 40
Evaluation of metabolic response with F-18-FDG PET-CT in patients with advanced or recurrent thymic epithelial tumors 40
Follow-up of solitary plasmacytoma by 99mTc-sestamibi scintigraphy 39
18F-FDG-PET/CT and 111In-Octreotide SPECT in the Evaluation of Patients with Neuroendocrine Lung Tumors 39
Evidence of Brown Adipose Tissue Astivity assessed by 18F-FDG-PET/CT in Females with Constitutional Leanness. 38
Washout of 99mTc-Sestamibi in predicting response to chemoterapy in patients with multiple myeloma 38
Functional imaging of multidrug resistance in breast cancer 38
Sentinel lymph node identification in breast cancer patients. 37
Sestamibi and FDG-PET scans to support diagnosis of jaw osteonecrosis. 37
New frontiers of nuclear medicine. 37
Coordinate up-regulation of Sp1 DNA-binding activity and urokinase receptor expression in breast carcinoma 36
Sorafenib in advanced iodine-refractory differentiated thyroid cancer: efficacy, safety and exploratory analysis of role of serum thyroglobulin and FDG-PET 36
18F-FDG-PET/CT, 99mTc-MIBI and MRI in the Prediction of Outcome of Patients with Multiple Myeloma 35
Combined Imaging With F-18-FDG-PET/CT and In-111-Labeled Octreotide SPECT for Evaluation of Thymic Epithelial Tumors 35
Functional imaging of multidrug resistant phenotype by 99mTc-MIBI scan in patients with multiple myeloma 34
Nuclear imaging in cancer theranostics 34
99mTc-MIBI in the evaluation of breast cancer biology 34
Monitoring reversal of MET-mediated resistance to EGFR tyrosine kinase inhibitors in non-small cell lung cancer using 3'-deoxy-3'-[18F]-fluorothymidine positron emission tomography 34
Gefitinib induction of in vivo detectable signals by Bcl-2/Bcl-X-L modulation of inositol trisphosphate receptor type 3 32
18F-FDG-PET/CT and 111In-Octreotide SPECT in Patients with Metastatic Medullary Thyroid Carcinoma 32
Lymph node mapping and sentinel lymph node biopsy for evaluation of axillary lymph node status in early invasive breast cancer 31
Stato dell'arte dell'imaging preclinico in oncologia 31
Reversal of Warburg Effect and Reactivation of Oxidative Phosphorylation by Differential Inhibition of EGFR Signaling Pathways in Non-Small Cell Lung Cancer 30
. A Single-Center, Open-Label, Phase II, Proof-of-Concept Study with Pasireotide LAR in patients with progressive medullary thyroid cancer (MTC) and the combination with RAD001 upon progression 30
18F-FLT PET/CTas a surrogate biomarker for synergy quantification in EGFR targeted combination therapy of NSCLC 30
Bone Scintigraphy and SPECT/CT in Bisphosphonate-Induced Osteonecrosis of the Jaw 28
Oncologia. In "Medicina Nucleare. Metodologie ed Applicazioni Diagnostiche". 27
PET/CT in cancer research: from preclinical to clinical applications 26
Contrast enhanced multi-detector CT and MR findings of a well-differentiated pancreatic vipoma. 26
Evidence of brown fat activity in constitutional leanness 26
A Single-Center, Open-Label, Phase II, Proof-of-Concept Study with Pasireotide LAR in patients with progressive medullary thyroid cancer (MTC): preliminary data. 25
Role of 68Ga-DOTATATE PET/CT in patients with multiple endocrine neoplasia type 1 (MEN1) 24
Molecular imaging for detection of sensitivity and resistance to EGFR tyrosine kinase inhibitors in non-small cell lung cancer 24
Bone Marrow uptake of 99mTc-MIBI in patients with multiple myeloma - Reply 21
Totale 3.672
Salva come PNG Salva come JPEG
Categoria #
all - tutte 12.115
article - articoli 10.956
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 531
Totale 23.602
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2023/202423 0 0 0 0 0 0 0 0 1 7 10 5
2024/20251.213 8 13 88 58 321 30 16 37 39 117 259 227
2025/20261.995 96 163 157 236 436 94 280 68 112 116 113 124
2026/2027441 137 110 194 0 0 0 0 0 0 0 0 0
Totale 3.672